Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

Li, Jin; Qin, Shukui; Xu, Rui‐Hua; Shen, Lin; Xu, Jianming; Bai, Yuxian; Yang, Lei; Deng, Yanhong; Chen, Zhen-dong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Fan, Songhua; Ye, Hua; Su, Weiguo

doi:10.1001/jama.2018.7855

Public

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

Published in JAMA • Jun 26, 2018

Authors:

Jin Li

Shukui Qin

Rui‐Hua Xu

Abstract

Importance: Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. Objective: To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with m...

Subject

Medicine

Internal medicine

Colorectal cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!